drugset / Trial / NCT01788475

Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery

NCT01788475 ↗

Terminated 3 enrolled Lahey Clinic
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Currently medications injected intravitreally in previously vitrectomized eyes have a very short half-life due to enhanced clearance of the drug. The use of the Ozurdex (dexamethasone) implant may allow sustained levels of steroid delivery to patients with diabetic macular edema that have undergone prior vitrectomy. The sustained steroid levels may lead to improved central retinal thickness measurements and improved visual acuity.

Timeline

Start
2013-02-22
Primary completion
2014-11
Completion
2014-11-12

Outcome

Outcome not reported

Stopped: “Study withdrawn by Investigator”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule 0.7 mg Intravitreal